



## Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

May 8, 2013

CARMIEL, Israel, May 8, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 14th Annual Israeli Conference on Sunday, May 12, 2013 at 3:35PM IDT. The conference is being held at the David Intercontinental Hotel in Tel Aviv, Israel.

### About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.

CONTACT: Investor Contact

Marcy Nanus  
The Trout Group, LLC  
646-378-2927 ☐  
[mnanus@troutgroup.com](mailto:mnanus@troutgroup.com)

Media Contact

Kari Watson  
MacDougall Biomedical Communications  
781-235-3060 ☐  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)

Protalix BioTherapeutics, Inc.